Compare Panels - Page 30

To add a panel to the list of panels you would like to compare, click the "Compare" button. You will be able to see which tests are included with the panels you select. You must choose at least two panels with a maximum of four panels.

Fetal Fibronectin *Build Your Own Panel Eligible [?]	$626	Compare Info
Description: Fetal fibronectin is a protein that performs two roles during pregnancy. It is produced by the placenta and acts as the glue that attaches the placenta to the uterine wall. In late pregnancy, it acts as a lubricant, aiding in the passage of the newborn through the vaginal canal. Amniotic fluid contains fetal fibronectin and when the membranes leak, can be detected in a cervicovaginal collection. This can be used as a predictor of pre-term delivery, defined as less than 37 weeks gestation. Categories: Price: $626
Fetal Hemoglobin *Build Your Own Panel Eligible [?]	$323	Compare Info
Description: Fetal hemoglobin is increased in sickle cell anemia, leukemias, beta-thalassemia and hereditary persistence of fetal hemoglobin. The production of fetal hemoglobin may be triggered as a response to sickle crisis. Categories: Price: $323
FH Gene Sequencing and Deletion/Duplication *Build Your Own Panel Eligible [?]	$628	Compare Info
Description: This test includes sequencing and deletion/duplication analysis of the FH gene. A pathogenic variant in the FH gene is consistent with a diagnosis of hereditary leiomyomatosis and renal cell cancer (HLRCC). Individuals with HLRCC have an elevated risk of developing renal cell cancer and cutaneous and uterine leiomyomas. Individuals with HLRCC may rarely develop cutaneous and uterine leiomyosarcomas, pheochromocytomas, and paragangliomas. Categories: Price: $628
FIB-4 Index Panel with Reflex to Enhanced Liver Fibrosis (ELF) Score *Build Your Own Panel Eligible [?]	$49	Compare Info
Description: This reflex provides a cost-effective, medically justified, and guideline supported approach to evaluating a patient at risk of NAFLD with liver fibrosis. If the FIB-4 index is ≥1.30, the ELF score is performed. Categories: Price: $49
Fibrin Monomer *Build Your Own Panel Eligible [?]	$292	Compare Info
Description: The Fibrin monomer assay is a qualitative test for the detection of soluble fibrin monomers in plasma. Fibrin monomers are an intermediate product of thrombin proteolysis of fibrinogen. With disseminated intravascular coagulation (DIC) there is an excess of thrombin generation and therefore detectable levels of soluble fibrin monomer. This test may be used in combination with other markers (platelet count, fibrinogen level, D-dimer) and the clinical scenario to determine the presence of DIC. Categories: Price: $292
Fibrinogen Activity *Build Your Own Panel Eligible [?]	$55	Compare Info
Description: Fibrinogen is essential for the formation of a blood clot. Deficiency can produce mild to severe bleeding disorders. The Fibrinogen Activity test is used to aid in the diagnosis of homozygous and heterozygous fibrinogen deficiency as well as dysfibrinogenemia. A significant deviation from the normal range may require further evaluation by your physician. Includes: Fibrinogen Activity Alternative Name(s) Factor I Patient Instructions: No fasting needed. Categories: Blood and blood diseases, Price: $55
Fibrinogen Antigen *Build Your Own Panel Eligible [?]	$133	Compare Info
Description: Low levels of fibrinogen are associated with bleeding most commonly secondary to liver disease or Disseminated Intravascular Coagulation (DIC). Fibrinogen is an acute phase reactant and thus elevated levels may be associated with inflammation. Increased concentrations are also associated with increased risk of atherosclerosis. Diagnosis of homozygous and heterozygous fibrinogen deficiency as well as dysfibrinogenemia; diagnosis of disseminated intravascular coagulation; fibrinogen levels can be used to assess the effectiveness of thrombolytic therapy. PT. WILL NEED HEMATOCRIT TO HAVE TEST PERFORMED. If unavailable pt. can order a CBC (complete Blood Count) to obtain a hematocrit. Significant deviations from the normal range may require further evaluation by your physician. Includes: Fibrinogen Antigen Patient Instructions: Overnight fasting is required. Fasting is defined as no consumption of food or beverage other than water for at least 8 hours before testing. Categories: Blood and blood diseases, Price: $133
Fibrinogen Comprehensive Panel without Consultation *Build Your Own Panel Eligible [?]	$446	Compare Info
Description: Check your blood clotting risk Screen for hidden inflammation levels Monitor your heart disease risk Categories: Price: $446
Fibrinogen Degradation Products (FDP) *Build Your Own Panel Eligible [?]	$323	Compare Info
Description: Screening test to aid in diagnosis of Disseminated Intravascular Coagulation (DIC) and Acute Occlusive Vascular Disease. Categories: Price: $323
Fibrinolysis Comprehensive Panel *Build Your Own Panel Eligible [?]	$1714	Compare Info
Description: An increase in PAI-1 antigen is associated with an increased risk for post-operative venous thrombosis, myocardial infarction, and (probably) stroke. A severe deficiency of alpha-2 antiplasmin or PAI-1 antigen has been associated with bleeding. A shortened euglobulin lysis time correlates with a severe deficiency of alpha-2 antiplasmin or PAI-1 antigen. Elevations in fibrin monomer, fibrinogen degradation products, and D-dimer usually indicate vascular thrombosis (mainly venous) but are also associated with malignancy and infection. Conversely, a normal D-dimer and/or negative fibrin monomer suggests the absence of deep venous thrombosis and pulmonary emboli. Marked reduction in plasminogen has been associated with a prothrombotic state, and an elevated TPA level is a risk marker of coronary artery disease. Categories: Price: $1714
Ficus Species (k81) IgE *Build Your Own Panel Eligible [?]	$49	Compare Info
Description: Ficus benjamina (Fb) is a tropical non-flowering plant used ornamentally in homes and public places such as offices and hospitals. The allergens are located in the sap of the plant, as well as in dust collected from leaf surfaces and on the floor, where the allergens may persist of several months after removal of the plant. The main route for sensitization is likely inhalation of airborne dust emanating from the leaves of the plant. Non-atopic patients have been reported to develop allergic rhinoconjunctivitis, contact urticaria and asthma caused by Fb. A frequent association between sensitization to Ficus species and natural rubber latex from Hevea brasiliensis has been attributed to cross-reacting IgE antibodies. Categories: Price: $49
Fig (Ficus carica) (f328) IgE *Build Your Own Panel Eligible [?]	$80	Compare Info
Description: Pinpoint fig allergies causing your symptoms Clarify unexplained reactions to certain foods Reveal hidden triggers affecting your health Categories: Allergy blood testing, Price: $80
Fighter's Competition Clearance Panel	$314	Compare Info
Description: Professional fighters (Boxers, Mixed Martial Arts Competitors, etc.) are required to have testing in order to qualify for competitions. Although the required tests may vary by state, this panel includes the preliminary testing required by most states. It is suggested that you confirm the tests listed in this panel will cover the requirements of your area. Significant deviations from the normal range may require further evaluation/interpretation by your physician. Includes: Complete Blood Count / CBC (includes Differential and Platelets): WBC, RBC, Hemoglobin, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count, MPV and Differential (Absolute and Percent - Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils) Hepatitis B Surface Antigen (HBsAg) with Reflex Confirmation Hepatitis C Antibody with Reflex HIV 1/2 Antigen and Antibodies, Fourth Generation with Reflex Confirmation Note: Confirmation testing is performed on reactive results only if initial values fall within a designated range requiring additional confirmation. If HIV Antigen and Antibody, 4th Generation Screen is Repeatedly Reactive, HIV-1/2 Antibody Differentiation will be performed If HIV-1/2 Antibody Differentiation is Indeterminate or Negative, HIV-1 RNA, Qualitative, Real-Time PCR will be performed Patient Instructions: Some tests in this panel may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H or coenzyme R). Patient should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample. Categories: Blood and blood diseases, Infectious diseases, STD’s detection & monitoring, Price: $314
Filaria Antibody (IgG4) *Build Your Own Panel Eligible [?]	$448	Compare Info
Description: Detect early signs of parasite infection Screen for causes of long-lasting swelling Identify possible reasons for unexplained fever Includes: Filaria Antibody (IgG4) Categories: Price: $448
Finch Feathers (re214) IgE *Build Your Own Panel Eligible [?]	$49	Compare Info
Description: This allergen-specific IgE antibody test quantifies an individual’s IgE response to finch feathers. It is an in vitro quantitative assay that is intended to be used in conjunction with other clinical information to aid in the diagnosis of allergic diseases [1]. While allergen-specific serum IgE testing is considered comparable to skin testing in many instances, both the American Academy of Allergy, Asthma, and Immunology and the American College of Allergy, Asthma, and Immunology recognize that allergen-specific serum IgE testing may be preferred in some clinical situations. These include 1) the presence of widespread skin disease, 2) the recent use of antihistamines or other medications that can affect the results of allergy skin tests, 3) uncooperative patients, and 4) medical history suggesting that allergen skin testing would pose a significant risk for a serious allergic reaction [1]. A definitive clinical diagnosis of allergy should not be based on the results of any single diagnostic method, but should be made by a trained healthcare provider after all clinical and laboratory findings have been evaluated. More specific information about this allergen can be found at http://www.phadia.com/en/products/allergy-testing-products/immunocap-allergen-information/epidermals-and-animal-proteins/allergens/finch-feathers/ Reference 1. Bernstein IL, et al. Ann Allergy Asthma Immunol. 2008;100(Suppl 3):S1-S148. Categories: Price: $49
Fire Ant (i70) IgE *Build Your Own Panel Eligible [?]	$49	Compare Info
Description: This test detects the presence of specific IgE against fire ants. A positive test only indicates that a person is sensitized and potentially allergic to this allergen. A diagnosis of allergy requires clinical signs and symptoms that appear to be associated with exposure to the allergen in addition to the detection of markers of IgE sensitization [1].More specific information about this allergen can be found on the following website: https://www.thermofisher.com/phadia/us/en/resources/allergen-encyclopedia.htmlReference1. Bernstein IL, et al. Ann Allergy Asthma Immunol. 2008;100(3 Suppl 3):S1-S148. Categories: Price: $49
Firebush (w17) IgE *Build Your Own Panel Eligible [?]	$49	Compare Info
Description: This test quantifies an individual's IgE response to firebush. Allergen-specific serum IgE testing is considered comparable to skin testing and may be preferred in some clinical situations. However, a positive test result only indicates that a patient is sensitized to the allergen of concern. Many IgE-sensitized individuals do not develop any symptoms when exposed to the allergen. A diagnosis of allergy should only be made by a trained medical provider after conducting a thorough clinical evaluation [1].More specific information about this allergen can be found on the following website: https://www.thermofisher.com/phadia/us/en/resources/allergen-encyclopedia.htmlReference 1. Bernstein IL, et al. Ann Allergy Asthma Immunol. 2008;100(3 Suppl 3):S1-S148. Categories: Price: $49
First Trimester Screen, hCG *Build Your Own Panel Eligible [?]	$321	Compare Info
Description: To screen for Down Syndrome and Trisomy 18 at 10.0-13.9 weeks gestation. Categories: Price: $321
First Trimester Screen, Hyperglycosylated hCG (h-hCG) *Build Your Own Panel Eligible [?]	$599	Compare Info
Description: To screen for Down syndrome and trisomy 18 at 9.0-13.9 weeks gestation. Categories: Price: $599
FISH, ABL1 *Build Your Own Panel Eligible [?]	$825	Compare Info
Description: High-risk B-ALL; BCR-ABL1-like B-ALL or Ph-like B-ALL with ABL class fusions diagnosis and evaluation for targeted therapy. Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referred to as a BCR-ABL-1-like ALL, is a high-risk subset with a gene expression profile that shares significant overlap with that of Ph-positive (Ph+) ALL and is suggestive of active kinase signaling. It exhibits adverse clinical features, confers poor prognosis and harbors a diverse range of genetic alterations that active cytokine receptors genes and kinase signaling pathways making it amenable to treatment with tyrosine kinase inhibitor (TKI) therapy. Categories: Price: $825
FISH, ABL2 *Build Your Own Panel Eligible [?]	$825	Compare Info
Description: High-risk B-ALL; BCR-ABL1-like B-ALL or Ph-like B-ALL with ABL class fusions diagnosis and evaluation for targeted therapy. Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referred to as a BCR-ABL-1-like ALL, is a high-risk subset with a gene expression profile that shares significant overlap with that of Ph-positive (Ph+) ALL and is suggestive of active kinase signaling. It exhibits adverse clinical features, confers poor prognosis and harbors a diverse range of genetic alterations that active cytokine receptors genes and kinase signaling pathways making it amenable to treatment with tyrosine kinase inhibitor (TKI) therapy. Categories: Price: $825
FISH, ALK 2p23 Rearrangement, Lung Cancer (NSCLC) *Build Your Own Panel Eligible [?]	$1168	Compare Info
Description: Non-small cell lung cancer is the leading cause of cancer death worldwide. Tyrosine kinase inhibitors have been demonstrated to reduce lung cancer cell proliferation. The therapeutic efficacy of inhibiting ALK in tumors that were selected by ALK positivity using FISH has been demonstrated in an early-phase clinical trial of a small molecular inhibitor of the ALK tyrosine kinase. The Vysis ALK Break Apart FISH probe kit is a qualitative test to detect rearrangements involving the ALK gene in formalin-fixed paraffin embedded non-small cell lung cancer tissue specimens to aid in identifying those patients eligible for treatment with XALKOR (crizotinib). Categories: Price: $1168
FISH, ALL, +4, +10, +17 *Build Your Own Panel Eligible [?]	$1072	Compare Info
Description: Detect chromosome changes linked to cancer Monitor disease progression over time Screen for specific genetic abnormalities Categories: Price: $1072
FISH, ALL, Extended Panel *Build Your Own Panel Eligible [?]	$5259	Compare Info
Description: This panel uses fluorescence in situ hybridization (FISH) to detect an extended set of common genetic abnormalities associated with B-cell acute lymphoblastic leukemia (B-ALL) and may aid in risk stratification and treatment decisions. These genetic abnormalities include the following: MYC rearrangement, the CDKN2A deletion, IGH rearrangement, TCF3 (E2A) rearrangement resulting from the t(1;19)(q23;p13) translocation, the BCR/ABL1 fusion gene resulting from the t(9;22)(q34;q11.2) translocation, the ETV6/RUNX1 (TEL/AML1) fusion gene resulting from the t(12;21)(p13;q22) translocation, KMT2A (MLL) rearrangement, intrachromosomal amplification of chromosome 21 (iAMP21), and trisomy of chromosomes 4, 10, and 17.While laboratory diagnosis of B-ALL generally requires morphologic evaluation and immunophenotyping, identifying genetic abnormalities is essential for risk stratification and patient management [1,2]. The College of American Pathologists and the American Society of Hematology recommend testing children with suspected or confirmed B-ALL for the following: the BCR/ABL1 fusion gene resulting from the t(9;22)(q34;q11.2) translocation, the ETV6/RUNX1 fusion gene resulting from the t(12;21)(p13;q22) translocation, KMT2A translocation, iAMP21, and trisomy 4 and 10 [3].A combination of genetic techniques is often involved in identifying genetic abnormalities. FISH testing is complementary to conventional cytogenetic analysis (karyotyping) and can be used to detect common cytogenetic abnormalities, especially cryptic ones not identified by karyotyping, such as the ETV6/RUNX1 fusion gene caused by t(12;21)(p13;q22) and iAMP21 (also detectable with FISH for ETV6/RUNX1) [1,2]. However, because FISH is limited to probing specific chromosomal regions, it does not replace conventional cytogenetic analysis or chromosomal microarray for screening unknown abnormalities.\|The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.References1. Naresh KN, et al. B-cell lymphoid proliferations and lymphomas. In: WHO Classification of Tumours Editorial Board. The World Health Organization Classification of Haematolymphoid Tumours. 5 Beta V2 ed. IARC Press; 2022:chap 4. Accessed June 8, 2023. https://tumourclassification.iarc.who.int2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Acute lymphoblastic leukemia. Version 2.2023. Updated July 28, 2023. https://www.nccn.org3. Arber DA, et al. Arch Pathol Lab Med. 2017;141(10):1342-1393 Categories: Price: $5259
FISH, ALL/MPD, del9p21/+9 *Build Your Own Panel Eligible [?]	$1206	Compare Info
Description: Monitor chromosome 9 cancer markers Track blood cancer treatment progress Detect genetic changes over time Categories: Price: $1206
FISH, ALL/NHL, MYC-BA, 8q24 Rearrangement *Build Your Own Panel Eligible [?]	$825	Compare Info
Description: This fluorescence in situ hybridization (FISH) assay uses a break-apart probe to detect the MYC translocation. The results of this test may aid in the diagnosis, risk stratification, and treatment decisions of B cell neoplasms.Rearrangements of the MYC (or c-MYC) gene, which encodes a transcription factor, are associated with B cell neoplasms including Burkitt lymphoma (BL), diffuse large B cell lymphoma (DLBCL), and plasmablastic lymphoma [1]. The MYC arrangements occur in all patients with BL and 5% to 8% of patients with DLBCL [2]; most are caused by translocation of MYC to the IGH, IGK, or IGL locus [1]. Because this FISH assay with a MYC break-apart probe can detect MYC translocation with various partner genes, it is the optimal assay for the evaluation of the MYC locus in patients with BL and DLBCL [3]. However, further testing may be needed to identify a specific translocation partner gene.A combination of genetic techniques is often involved in identifying genetic abnormalities. FISH testing is complementary to conventional cytogenetic analysis (karyotyping) and can be used to detect common cytogenetic abnormalities. However, because FISH is limited to probing specific chromosomal regions, it does not replace conventional cytogenetic analysis or chromosomal microarray for screening unknown abnormalities.The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.References1. Naresh KN, et al. B-cell lymphoid proliferations and lymphomas. In: WHO Classification of Tumours Editorial Board. The World Health Organization Classification of Haematolymphoid Tumours. 5 Beta V2 ed. IARC Press; 2022:chap 4. Accessed June 12, 2023. https://tumourclassification.iarc.who.int2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). B-cell lymphomas. Version 5.2023. Updated July 7, 2023.https://www.nccn.org3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Pediatric aggressive mature B-cell lymphomas. Version 1.2023. Updated April 4, 2023. https://www.nccn.org Categories: Price: $825
FISH, ALL, Pre-B Panel *Build Your Own Panel Eligible [?]	$2635	Compare Info
Description: This panel uses fluorescence in situ hybridization (FISH) to detect common genetic abnormalities associated with B-cell acute lymphoblastic leukemia (B-ALL) and may aid in risk stratification and treatment decisions. These genetic abnormalities include the following: KMT2A (MLL) translocation, the BCR/ABL1 fusion gene resulting from the t(9;22)(q34;q11.2) translocation, the ETV6/RUNX1 (TEL/AML1) fusion gene resulting from the t(12;21)(p13;q22) translocation, and trisomy of chromosomes 4, 10, and 17.While laboratory diagnosis of B-ALL generally requires morphologic evaluation and immunophenotyping, identifying genetic abnormalities is essential for risk stratification and patient management [1,2]. The College of American Pathologists and the American Society of Hematology recommend testing children with suspected or confirmed B-ALL for the following: trisomy 4 and 10, the BCR/ABL1 fusion gene resulting from the t(9;22)(q34;q11.2) translocation, the ETV6/RUNX1 fusion gene resulting from the t(12;21)(p13;q22) translocation, KMT2A translocation, and intrachromosomal amplification of chromosome 21 (iAMP21) [3].A combination of genetic techniques is often involved in identifying genetic abnormalities. FISH testing is complementary to conventional cytogenetic analysis (karyotyping) and can be used to detect common cytogenetic abnormalities, especially cryptic ones not identified by karyotyping, such as the ETV6/RUNX1 fusion gene caused by t(12;21)(p13;q22) and iAMP21 (also detectable with FISH for ETV6/RUNX1) [1,2]. However, because FISH is limited to probing specific chromosomal regions, it does not replace conventional cytogenetic analysis or chromosomal microarray for screening unknown abnormalities.The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.References1. Naresh KN, et al. B-cell lymphoid proliferations and lymphomas. In: WHO Classification of Tumours Editorial Board. The World Health Organization Classification of Haematolymphoid Tumours. 5 Beta V2 ed. IARC Press; 2022:chap 4. Accessed June 8, 2023. https://tumourclassification.iarc.who.int2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Acute lymphoblastic leukemia. Version 2.2023. Updated July 28, 2023. https://www.nccn.org3. Arber DA, et al. Arch Pathol Lab Med. 2017;141(10):1342-1393. Categories: Price: $2635
FISH, ALL, TCF3/PBX1, t(1:19)(q23.3:p13.3) *Build Your Own Panel Eligible [?]	$825	Compare Info
Description: FISH testing with the TCF3-PBX1 dual fusion dual color probe allows detection of balanced and unbalanced translocations involving 1q23.3 (PBX1) and 19p13.3 (TCF3). This translocation has been observed in acute lymphoblastic leukemia with a precursor-B immunophenotype. Furthermore, a variant translocation, involving 17q22 (HLF) and 19p13.3 (TCF3) can be detected with this probe. Categories: Price: $825
FISH, Alveolar Rhabdomyosarcoma (ARMS), FKHR, 13q14 Rearrangement *Build Your Own Panel Eligible [?]	$1088	Compare Info
Description: This fluorescence in situ hybridization (FISH) assay detects chromosome rearrangements of the FOXO1 (FKHR) gene located on chromosome 13q14.11. The results of this test may aid in the diagnosis and prognostic assessment of alveolar rhabdomyosarcoma (ARMS).ARMS accounts for 25% of rhabdomyosarcoma and commonly occurs between 10 to 25 years of age [1]. The majority of the patients with ARMS have FOXO1 rearrangements that result in the PAX3/FOXO1 (70%-90%) or PAX7/FOXO1 (10%-30%) fusion genes [1]. These characteristic fusion genes help distinguish ARMS from poorly differentiated embryonal rhabdomyosarcoma (ERMS), which is the most common type of rhabdomyosarcoma in children [1]. Further testing may be needed to identify each specific gene fusion. Patients with FOXO1 rearrangement gerenally have inferior prognosis than those without; patients with the PAX3/FOXO1 fusion gene have a worse prognosis than patients with the PAX7/FOXO1 fusion gene [1].The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.References 1. Fletcher CDM, et al. Soft tissue tumours. In: WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. 5th ed. IARC Press; 2020:chap 2. Accessed July 18, 2023. https://tumourclassification.iarc.who.int2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Soft tissue sarcoma. Version 2.2023. Updated April 25, 2023. https://www.nccn.org Categories: Price: $1088
FISH, AML, CBFB/MYH11, Inversion 16 *Build Your Own Panel Eligible [?]	$825	Compare Info
Description: This test is performed to detect the CBFB rearrangements such as inversion (16) and translocation t(16;16), by FISH (fluorescence in situ hybridization). This assay is useful for diagnosis of acute myeloid leukemia (AML) with inv(16) or t(16;16); CBFB-MYH11. Categories: Price: $825
FISH, AML/MDS, -7/Deletion 7q31 *Build Your Own Panel Eligible [?]	$1206	Compare Info
Description: This fluorescence in situ hybridization (FISH) assay detects monosomy 7 and deletion in chromosome 7q31 (D7S522 locus). The results of this test may aid in the diagnosis and prognostic assessment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).Monosomy 7 and del(7q) are recurrent genetic abnormalities associated with myeloid disorders, including MDS and AML. In the diagnosis of MDS, monosomy 7 and del(7q) are considered MDS-associated karyotypes; the presence of one of them can be used to help establish the diagnosis [1]. According to the Revised International Prognostic Scoring System (IPSS-R), the presence of del(7q) in patients with MDS indicates intermediate cytogenetic risk, while the presence of monosomy 7 or double abnormalities including del(7q) or monosomy 7 indicates poor cytogenetic risk [2]. In patients with AML, the presence of monosomy 7 indicates poor/adverse prognosis [3]. Monosomy 7, 7q deletion, and loss of 7q are defining cytogenetic abnormalities of AML, myelodysplasia-related (AML-MR) [4].A combination of genetic techniques is often involved in identifying genetic abnormalities. FISH testing is complementary to conventional cytogenetic analysis (karyotyping) and can be used to detect common cytogenetic abnormalities. However, because FISH is limited to probing specific chromosomal regions, it does not replace conventional cytogenetic analysis or chromosomal microarray for screening unknown abnormalities.The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.References1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Myelodysplastic syndromes. Version 1.2023. Updated September 12,2022. https://www.nccn.org 2. Greenberg PL, et al. Blood. 2012;120(12):2454-2465.3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Acute myeloid leukemia. Version 4.2023. Updated July 11, 2023. https://www.nccn.org4. Khoury DJ, et al. Myeloid proliferations and neoplasms. In: WHO Classification of Tumours Editorial Board. The World Health Organization Classification of Haematolymphoid Tumours. 5 Beta V2 ed. IARC Press; 2022:chap 2. Accessed June 16, 2023. https://tumourclassification.iarc.who.int Categories: Price: $1206
FISH, AML/MDS, CEP 8, Trisomy 8 *Build Your Own Panel Eligible [?]	$1206	Compare Info
Description: This test uses fluorescence in situ hybridization (FISH) to detect trisomy 8 in patients with myeloid disorders. This FISH test may be used to aid standard cytogenetic testing to increase the detection rate of trisomy 8 when the result of standard cytogenetic testing is uncertain or when the specimen is suboptimal [1,2]. Identification of trisomy 8 in patients with myeloid disorders may inform prognosis and aid in follow-up testing to monitor treatment outcomes [3-5].Trisomy 8 is a common abnormality in patients with myeloid disorders, such as chronic myeloid leukemia (CML), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPNs), myelodysplastic syndromes (MDS), and hematologic disorders not otherwise specified. Trisomy 8 is the most common numerical aberration in AML and the second-most common in MDS [3]. As a sole abnormality, trisomy 8 is associated with an intermediate prognosis in patients with AML [4]. In patients with MDS, trisomy 8 is also associated with an intermediate prognosis according to the Revised International Prognostic Scoring System (IPSS-R) [5]. Note that in the absence of defining morphological criteria, trisomy 8 is not considered definitive evidence of a hematologic neoplasm [6].Although trisomy 8 is strongly associated with myeloid malignancies, it is not specific for myeloid disorders. Trisomy 8 has been found in many other neoplastic disorders, such as lymphomas, lymphoblastic leukemias, desmoid tumors, and Dupuytren contracture [3]. In addition, myeloid disorders often harbor many recurring cytogenetic aberrations other than trisomy 8. Thus, this assay does not serve as a stand-alone test for myeloid disorders [1].The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.⁠⁠⁠⁠⁠⁠⁠References1. CEP 8 SpectrumOrange DNA probe kit. Package insert. Abbott; 2012. Accessed April 3, 2022.2. Jenkins RB, et al. Blood. 1992;79(12):3307-3315.3. Paulsson K, Johansson B. Pathol Biol (Paris). 2007;55(1):37-48.4. Hemsing AL, at al. Expert Rev Hematol. 2019;12(11):947-958.5. Greenberg PL, et al. Blood. 2012;120(12):2454-2465.6. Swerdlow S, et al, eds. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Vol 2. 4th ed. IARC Press; 2017:104. Categories: Price: $1206
FISH, AML-NUP98 (11p15.4) *Build Your Own Panel Eligible [?]	$1109	Compare Info
Description: Structural chromosomal rearrangements of the Nucleoporin 98 (NUP98) gene have been reported in a wide range of hematologic neoplasms including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and T-cell acute lymphoblastic leukemia (T-ALL). Fusion of NUP98 gene to various fusion partners leads to generation of leukemogenic NUP98 fusion proteins and correlates with poor prognosis. The NUP98 FISH test will allow for the detection of NUP98 gene rearrangement to further classify prognostic risk in AML and guide therapy selection. Categories: Price: $1109
FISH, AML Targeted Panel *Build Your Own Panel Eligible [?]	$4590	Compare Info
Description: The Acute Myeloid Leukemia (AML) targeted FISH panel provide rapid detection of key WHO defining cytogenetic abnormalities that confirm diagnosis and disease classification, guide immediate and long-term therapy, and contribute to prognostication in patients with or suspected of having AML. The panel complements conventional cytogenetics and molecular testing and covers the following genomic alterations: t(8;21)(RUNX1::RUNX1T1), inv(16)/ t(16;16)(CBFB::MYH11), t(15;17)(PML::RARA), t(9;22)(BCR:: ABL1),11q23(KMT2A) rearrangements, and 17p13 (TP53) deletion. The results of this assay help distinguish AML subtypes (e.g., Acute Promyelocytic Leukemia, core-binding factor AML, AML with KMT2A rearrangement) from other myeloid neoplasms and support WHO classification when morphology and immunophenotype are insufficient. They ultimately enable accurate disease categorization which affects initial treatment choice, treatment urgency, and risk stratification:Favorable Prognosis (Core Binding Factor AML):- t(8;21)(q22;q22); RUNX1::RUNX1T1: a well-defined cytogenetic abnormality in "Core Binding Factor" (CBF) leukemia, this subtype frequently exhibits aberrant CD19 expression and is associated with high complete remission rates and favorable long-term survival.- inv(16)(p13.1q22) or t(16;16); CBFB::MYH11: a recurring cytogenetic abnormality in another CBF-AML subtype, it often presents with myelomonocytic features and abnormal eosinophils (AML-M4eo), and is associated with favorable prognosis.Distinct Treatment Pathway- t(15;17)(q24.1;q21.2); PML::RARA: defines Acute Promyelocytic Leukemia (APL). It is a medical emergency due to high early mortality from coagulopathy but is highly curable with targeted therapies like All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (ATO).Adverse or Variable Prognosis- t(9;22)(q34.1;q11.2); BCR::ABL1, also known as the "Philadelphia Chromosome" translocation: characteristic of CML, it occurs in rare cases of AML and is associated with a highly aggressive clinical course and low survival rate, often requiring intensive chemotherapy combined with Tyrosine Kinase Inhibitors (TKI).- 11q23 (KMT2A) rearrangements: rearrangements of KMT2A gene (previously known as MLL) involve many partner genes and generally carry an intermediate to adverse prognosis. They are common in infant leukemias and therapy-related AML.- 17p13 deletion (TP53): deletions of the TP53 gene define a highly treatment-resistant, high-risk subtype, typically associated with a complex karyotype and very poor prognosis. Categories: Price: $4590
FISH, APL, PML/RARA, Translocation 15, 17 *Build Your Own Panel Eligible [?]	$809	Compare Info
Description: This fluorescence in situ hybridization (FISH) assay uses dual-fusion probes to detect the t(15;17)(q24;q21) translocation that results in the PML/RARA fusion gene. The results of this test may aid in the diagnosis of acute promyelocytic leukemia (APL).APL is a subtype of acute myeloid leukemia with distinct clinical and histopathologic features. Most patients with APL harbor a translocation that involves the RARA gene on chromosome 17 and the PML gene on chromosome 15, which results in a PML/RARA fusion gene [1]. The College of American Pathologists and the American Society of Hematology recommend rapid detection of the PML/RARA fusion gene for patients with suspected APL [2]. A FISH test with dual-fusion probes can be used to detect the PML/RARA fusion gene and help establish the diagnosis. Because a FISH test does not differentiate PML/RARA isotypes, which is needed for subsequent monitoring for measurable residual disease (MRD), a polymerase chain reaction (PCR) test is recommended by the European LeukemiaNet in addition to the FISH test or as an alternative [3].Approximately 5% of patients with APL harbor variant RARA translocations that involve partner genes other the PML gene [1]. A FISH test with the RARA break-apart probe can be used for assessing the RARA status when morphology is suspicious for APL, but the PML/RARA fusion gene is not detected.A combination of genetic techniques is often involved in identifying genetic abnormalities. FISH testing is complementary to conventional cytogenetic analysis (karyotyping) and can be used to detect common cytogenetic abnormalities. However, because FISH is limited to probing specific chromosomal regions, it does not replace conventional cytogenetic analysis or chromosomal microarray for screening unknown abnormalities.The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.References1. Khoury DJ, et al. Myeloid proliferations and neoplasms. In: WHO Classification of Tumours Editorial Board. The World Health Organization Classification of Haematolymphoid Tumours. 5 Beta V2 ed. IARC Press; 2022:chap 2. Accessed June 8, 2023. https://tumourclassification.iarc.who.int2. Arber DA, et al. Arch Pathol Lab Med. 2017;141(10):1342-1393.3. Sanz MA, et al. Blood. 2019;133(15):1630-1643. Categories: Price: $809
FISH, APL, RARA-BA *Build Your Own Panel Eligible [?]	$1088	Compare Info
Description: This fluorescence in situ hybridization (FISH) assay uses a break-apart probe to detect chromosomal translocations involving the RARA gene region at chromosome 17q21. The results of this test may aid in the diagnosis of acute promyelocytic leukemia (APL) with variant RARA translocations.APL is a subtype of acute myeloid leukemia with distinct clinical and histopathologic features. Most patients with APL harbor a translocation that involves the RARA gene on chromosome 17 and the PML gene on chromosome 15, which results in a PML/RARA fusion gene [1]. The College of American Pathologists and the American Society of Hematology recommend rapid detection of the PML/RARA fusion gene for patients with suspected APL [2]. A FISH test with dual-fusion probes can be used to detect the PML/RARA fusion gene and help establish the diagnosis. However, approximately 5% of patients with APL harbor variant RARA translocations that involve partner genes other than PML [1]. This FISH test with the RARA break-apart probe is useful for assessing the RARA status when morphology is suspicious for APL but the PML/RARA fusion gene is not detected.A combination of genetic techniques is often involved in identifying genetic abnormalities. FISH testing is complementary to conventional cytogenetic analysis (karyotyping) and can be used to detect common cytogenetic abnormalities. However, because FISH is limited to probing specific chromosomal regions, it does not replace conventional cytogenetic analysis or chromosomal microarray for screening unknown abnormalities.The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.References1. Khoury DJ, et al. Myeloid proliferations and neoplasms. In: WHO Classification of Tumours Editorial Board. The World Health Organization Classification of Haematolymphoid Tumours. 5 Beta V2 ed. IARC Press; 2022:chap 2. Accessed June 8, 2023. https://tumourclassification.iarc.who.int2. Arber DA, et al. Arch Pathol Lab Med. 2017;141(10):1342-1393. Categories: Price: $1088
FISH, APL with Reflex to RARA *Build Your Own Panel Eligible [?]	$809	Compare Info
Description: Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia with distinct clinical and histopathologic features. Historically one of the most lethal forms of acute myeloid leukemia, APL leads to disseminated intravascular coagulation and death when not diagnosed and treated. Treatment with all-trans-retinoic acid substantially improves survival in patients who have failed anthracycline chemotherapy or for whom anthracycline is contraindicated. Similarly, arsenic trioxide is beneficial in APL patients who have failed or have contraindications for treatment with anthracycline or retinoid-based therapy.Genetically, APL is characterized by a unique chromosomal anomaly. More than 99% of APL patients harbor a translocation between chromosomes 15 and 17, which fuses the retinoic acid receptor alpha (RARA) gene on chromosome 17 with the PML gene on chromosome 15. A short or a long transcript isoform is produced, depending on the PML breakpoint; the short isoform has been linked to poor outcome, but this association remains controversial. Detection of the PML/RARA t(15;17) translocation is diagnostic for APL, although the diagnosis can also be based on morphology. The presence of this translocation is necessary for response to all-trans-retinoic acid and arsenic trioxide. Thus, the PML/RARA t(15;17) assay is useful for diagnosis and predicting treatment response. It is also helpful for monitoring therapeutic response and MRD and for detecting early relapse.This RARA break-apart probe is useful for detecting variant RARA translocations with partners other than PML. Therefore, this testing is useful for verifying RARA status when morphology is suspicious for APL but t(15;17) FISH is negative. Categories: Price: $809
FISH, ATM and TP53 *Build Your Own Panel Eligible [?]	$2264	Compare Info
Description: The most common prognostically established cytogenetic abnormalities in CLL/SLL are 13q14 deletion, +12, TP53 (17p) deletion and ATM (11q) deletion. Although all these aberrations can be detected using the CLL/SLL FISH panel, the ATM and TP53 deletions status can be ordered separately. TP53 (17p) deletion predicts treatment failure with alkylating agents, fludarabine and short survival times. Patients with TP53 deletions should be treated with targeted therapy. ATM (11q) deletion is associated with marked lymphadenopathy, rapid disease progression, and unfavorable prognosis. In multivariate analysis, TP53 and ATM deletions provided independent prognostic information. In addition to CLL/SLL, ATM and TP53 deletions can also be seen in other B-cell lymphoproliferative disorders. Categories: Price: $2264
FISH, B-Cell Chronic Lymphocytic Leukemia Panel *Build Your Own Panel Eligible [?]	$1441	Compare Info
Description: ⁠⁠⁠⁠⁠⁠⁠This test is performed to detect the rearrangements of 6q21 (SEC63), 6q23 (MYB), ATM (11q22.3), centromere 12 (D12Z3), 13q14.3 (DLEU), 13q34 (LAMP1) and TP53 (17p13.1) regions, by FISH (fluorescence in situ hybridization). This assay is useful for prognostic assessment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Categories: Price: $1441
FISH, B-Cell Malignancy, IGH, 14q32 Rearrangement *Build Your Own Panel Eligible [?]	$854	Compare Info
Description: The splitting of IgH region of chromosome 14q32 is frequently implicated in translocations seen in a variety of hematological malignancies of B-cell origin. Categories: Price: $854
FISH, Burkitt's/NHL/ALL, IGH/MYC, t(8;14) *Build Your Own Panel Eligible [?]	$950	Compare Info
Description: The translocation T(8;14)(Q24.1;Q32) is assayed by FISH with probes from the regions C-MYC (8Q24.1) and IGH (14Q32). This assay is useful to diagnose Burkitt's type lymphoma and some cases of Acute Lymphoblastic Leukemia. Categories: Price: $950
FISH, Chromosome 20q Deletion *Build Your Own Panel Eligible [?]	$804	Compare Info
Description: This fluorescence in situ hybridization (FISH) assay detects chromosome 20q12 deletion and may aid in the diagnosis and prognostic assessment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).Deletion of chromosome 20q is a recurrent genetic abnormality associated with myeloid disorders, including MDS and AML. In the diagnosis of MDS, del(20q) is considered one of the MDS-associated karyotypes and can be used to help establish the diagnosis [1]. According to the Revised International Prognostic Scoring System (IPSS-R), del(20q) as a single anomaly in patients with MDS indicates good prognosis [2].A combination of genetic techniques is often involved in identifying genetic abnormalities. FISH testing is complementary to conventional cytogenetic analysis (karyotyping) and can be used to detect common cytogenetic abnormalities. However, because FISH is limited to probing specific chromosomal regions, it does not replace conventional cytogenetic analysis or chromosomal microarray for screening unknown abnormalities.The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.References1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Myelodysplastic syndromes. Version 1.2023. Updated September 12,2022. https://www.nccn.org2. Greenberg PL, et al. Blood. 2012;120(12):2454-2465. Categories: Price: $804
FISH, Chromosome -5/Deletion 5q31 *Build Your Own Panel Eligible [?]	$1206	Compare Info
Description: This fluorescence in situ hybridization (FISH) assay detects monosomy 5 and deletion in chromosome 5q31. The results of this test may aid in the diagnosis and prognostic assessment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).Chromosome 5 abnormalities are recurrent genetic abnormalities associated with myeloid disorders, including AML and MDS. In patients with AML, the presence of monosomy 5 or del(5q) indicates poor/adverse prognosis [1]. Loss of 5q due to unbalanced translocation or del(5q) is one of the defining cytogenetic abnormalities of AML, myelodysplasia-related (AML-MR) [2]. In patients with MDS, del(5q) is one of the MDS-associated karyotypes and can be used to help establish the diagnosis [3]. According to the Revised International Prognostic Scoring System (IPSS-R), the presence of del(5q) (with or without a second abnormality) in patients with MDS indicate good prognosis [4].A combination of genetic techniques is often involved in identifying genetic abnormalities. FISH testing is complementary to conventional cytogenetic analysis (karyotyping) and can be used to detect common cytogenetic abnormalities. However, because FISH is limited to probing specific chromosomal regions, it does not replace conventional cytogenetic analysis or chromosomal microarray for screening unknown abnormalities.The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.References1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Acute myeloid leukemia. Version 3.2023. Updated April 5, 2023. https://www.nccn.org2. Khoury DJ, et al. Myeloid proliferations and neoplasms. In: WHO Classification of Tumours Editorial Board. The World Health Organization Classification of Haematolymphoid Tumours. 5 Beta V2 ed. IARC Press; 2022:chap 2. Accessed June 16, 2023. https://tumourclassification.iarc.who.int3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Myelodysplastic syndromes. Version 1.2023. Updated September 12,2022. https://www.nccn.org4. Greenberg PL, et al. Blood. 2012;120(12):2454-2465. Categories: Price: $1206
FISH, Chromosome D13S319, Deletion 13q14 *Build Your Own Panel Eligible [?]	$1206	Compare Info
Description: This fluorescence in situ hybridization (FISH) assay detects deletions in chromosome 13q14.3 with a probe specific for the D13S319 locus. The results of this test may aid in the prognostic assessment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).The most common genetic abnormalities of CLL/SLL are del(13q), del(11q), trisomy 12, and del (17p). At least one of these 4 genetic abnormalities can be detected with FISH in >80% of patients with CLL/SLL [1]. Evaluation of these frequent genetic abnormalities is recommended for the investigation of prognosis [2] and may inform treatment decisions [3]. Del(13q) can be detected with FISH in 55% of patients with CLL/SLL [1]. Del(13q) results in the loss of the DLEU2/miR-15a/16-1 cluster, which has been implicated in the pathogenesis of CLL/SLL [4]. As a sole genetic abnormality, del(13q) is considered a favorable prognostic indicator [3].A combination of genetic techniques is often involved in identifying genetic abnormalities. FISH testing is complementary to conventional cytogenetic analysis (karyotyping) and can be used to detect common cytogenetic abnormalities. However, because FISH is limited to probing specific chromosomal regions, it does not replace conventional cytogenetic analysis or chromosomal microarray for screening unknown abnormalities.The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.References1. Dohner H, et al. N Engl J Med. 2000;343(26):1910-1916.2. Naresh KN, et al. B-cell lymphoid proliferations and lymphomas. In: WHO Classification of Tumours Editorial Board. The World Health Organization Classification of Haematolymphoid Tumours. 5 Beta V2 ed. IARC Press; 2022:chap 4. Accessed June 16, 2023. https://tumourclassification.iarc.who.int3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Chronic lymphocytic leukemia/small lymphocytic lymphoma. Version 3.2023. Updated June 12, 2023. https://www.nccn.org4. Klein U, et al. Cancer Cell. 2010;17(1):28-40. Categories: Price: $1206
FISH, Chromosome-Specific Probe (x1) *Build Your Own Panel Eligible [?]	$816	Compare Info
Description: Detect specific chromosome abnormalities precisely Screen for inherited genetic conditions early Track cancer-related chromosome changes closely Categories: Price: $816
FISH, Chromosome-Specific Probe (x1), Follow-up Study *Build Your Own Panel Eligible [?]	$736	Compare Info
Description: Monitor known chromosome changes over time Track genetic condition progress accurately Screen for treatment response patterns Categories: Price: $736
FISH, CLL, ATM, Deletion 11q22.3 *Build Your Own Panel Eligible [?]	$1206	Compare Info
Description: This fluorescence in situ hybridization (FISH) assay detects deletion of the ATM gene region in chromosome 11q22.3. The results of this test may aid in the prognostic assessment and treatment selection for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).The most common genetic abnormalities of CLL/SLL are del(13q), del(11q), trisomy 12, and del (17p). At least one of these 4 genetic abnormalities can be detected with FISH in >80% of patients with CLL/SLL [1]. Evaluation of these frequent genetic abnormalities is recommended for the investigation of prognosis [2] and may inform treatment decisions [3]. Del(11q) results in the loss of the ATM gene and can be detected with FISH in 18% of patients with CLL/SLL [1]. The presence of del(11q) is associated with marked lymphadenopathy and unfavorable prognosis [2,3].A combination of genetic techniques is often involved in identifying genetic abnormalities. FISH testing is complementary to conventional cytogenetic analysis (karyotyping) and can be used to detect common cytogenetic abnormalities. However, because FISH is limited to probing specific chromosomal regions, it does not replace conventional cytogenetic analysis or chromosomal microarray for screening unknown abnormalities.The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.References1. Dohner H, et al. N Engl J Med. 2000;343(26):1910-1916.2. Naresh KN, et al. B-cell lymphoid proliferations and lymphomas. In: WHO Classification of Tumours Editorial Board. The World Health Organization Classification of Haematolymphoid Tumours. 5 Beta V2 ed. IARC Press; 2022:chap 4. Accessed June 16, 2023. https://tumourclassification.iarc.who.int3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Chronic lymphocytic leukemia/small lymphocytic lymphoma. Version 3.2023. Updated June 12, 2023. https://www.nccn.org Categories: Price: $1206
FISH, CLL, CEP 12, Trisomy 12 *Build Your Own Panel Eligible [?]	$1206	Compare Info
Description: This fluorescence in situ hybridization (FISH) assay detects trisomy of chromosome 12 and may aid in the prognostic assessment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).The most common genetic abnormalities of CLL/SLL are del(13q), del(11q), trisomy 12, and del (17p). At least one of these 4 genetic abnormalities can be detected with FISH in >80% of patients with CLL/SLL [1]. Evaluation of these frequent genetic abnormalities is recommended for the investigation of prognosis [2] and may inform treatment decisions [3]. Trisomy 12 can be detected with FISH in 16% of patients with CLL/SLL [1] and is more likely to occur in patients with enlarged proliferation centers [2]. Although the genes involved in trisomy 12 are unknown, the presence of trisomy 12 confers an intermediate prognostic risk [3].A combination of genetic techniques is often involved in identifying genetic abnormalities. FISH testing is complementary to conventional cytogenetic analysis (karyotyping) and can be used to detect common cytogenetic abnormalities. However, because FISH is limited to probing specific chromosomal regions, it does not replace conventional cytogenetic analysis or chromosomal microarray for screening unknown abnormalities.The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.References1. Dohner H, et al. N Engl J Med. 2000;343(26):1910-1916.2. Naresh KN, et al. B-cell lymphoid proliferations and lymphomas. In: WHO Classification of Tumours Editorial Board. The World Health Organization Classification of Haematolymphoid Tumours. 5 Beta V2 ed. IARC Press; 2022:chap 4. Accessed June 16, 2023. https://tumourclassification.iarc.who.int3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Chronic lymphocytic leukemia/small lymphocytic lymphoma. Version 3.2023. Updated June 12, 2023. https://www.nccn.org Categories: Price: $1206
FISH, CML/ALL, bcr/abl, Translocation 9,22 *Build Your Own Panel Eligible [?]	$842	Compare Info
Description: This test uses fluorescence in situ hybridization (FISH) to detect molecular rearrangement of the BCR and ABL1 genes involved in translocation t(9;22). This translocation, resulting in an abnormally short chromosome 22 known as the Philadelphia chromosome (Ph), is associated with chronic myelogenous leukemia (CML), de novo acute myeloid leukemia, and acute lymphocytic leukemia (ALL) [1-3]. This test may also be used in the evaluation of Ph-negative CML and complex gene rearrangements [4].CML is defined as a myeloproliferative neoplasm with the presence of Ph. When blood and bone marrow morphology findings suggest CML, the diagnosis is confirmed by identifying Ph using chromosome analysis and/or by detecting the BCR-ABL1 fusion gene with PCR or FISH. In 5% to10% of CML patients who have complex translocations involving chromosomes 9, 22, and other chromosome(s), Ph cannot be identified by chromosome analysis. In these patients, FISH is especially useful for detecting BCR/ABL1 rearrangement [4]. Ph is also present in some adults (~25%) and children (2%-4%) with ALL [2]. This test can be used to identify ALL with the t(9;22) BCR/ABL1 rearrangement (Ph-positive ALL).FISH can be performed on bone marrow specimens and/or on peripheral blood. When bone marrow evaluation is not feasible, FISH on a peripheral blood specimen can be used to confirm the diagnosis of CML. The dual-fusion FISH assay used in this test has a low false-positive rate and can detect all variant translocations of Ph. However, this test is not quantitative and has not been adequately studied to confirm utility in monitoring response to treatment. qPCR is the most sensitive assay for measurement of BCR-ABL1 mRNA [1].The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.References1. NCCN clinical practice guidelines in oncology: Chronic myeloid leukemia, Version 1.2022. National Comprehensive Cancer Network. Accessed November 9, 2021. https://www.nccn.org/2. NCCN clinical practice guidelines in oncology: Acute lymphoblastic leukemia, Version 2.2021. National Comprehensive Cancer Network. Accessed November 9, 2021. https://www.nccn.org/3. Arber DA, et al. Blood. 2016;127(20):2391-2405.4. Albano F, et al. Mol Cancer. 2010;9:120. Categories: Price: $842
FISH, Cri Du Chat *Build Your Own Panel Eligible [?]	$790	Compare Info
Description: This test uses fluorescence in situ hybridization (FISH) technology to detect a deletion of the short arm of chromosome 5 in individuals with clinically suspected 5p- syndrome (cri du chat syndrome). Infants with this syndrome often have low birth weight, weak muscle tone, and a characteristic high-pitched cry that resembles that of a cat. Patients may also have developmental delay, intellectual disability, characteristic facial features, a small head, and dental malocclusions [1].5p- syndrome, though rare, is one of the most common structural chromosomal anomalies. It is caused by a partial or complete deletion of the short arm of chromosome 5. Clinical manifestation, severity, and progression of the disease largely depend on the type, size, and region of the deletion(s). Diagnosis is based on clinical findings and can be confirmed by chromosomal karyotyping. When the karyotype appears normal but clinical suspicion for 5p-syndrome is high, FISH or chromosomal microarray analysis may aid in diagnosis [1]. However, a negative FISH result (ie, no deletion detected) does not rule out 5p- syndrome.The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.Reference1. Ajitkumar A, et al. Cri du chat syndrome. In: StatPearls [Internet]. StatPearls Publishing; 2021. Accessed October 18, 2021. https://www.ncbi.nlm.nih.gov/books/NBK482460/ Categories: Price: $790

Top of page

View All

Questions or Concerns?